Gene and cell therapy for cystic fibrosis: From bench to bedside

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Conese, Massimo ^a,b   Ascenzioni, Fiorentina ^c   Boyd, A Christopher ^d   Coutelle, Charles ^e   De Fino, Ida ^a,f   De Smedt, Stefaan ^f   Rejman, Joanna ^f   Rosenecker, Joseph ^g   Schindelhauer, Dirk ^h   Scholte, Bob J ⁱ  

^a Institute for the Experimental Treatment of Cystic Fibrosis   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f GHENT UNIVERSITY   (Belgium)

^g UNIVERSITY OF MUNICH   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; CFTR; Cystic fibrosis; Gene delivery; Human artificial chromosome; In utero gene therapy; Stem cells; Vector development

Indexed keywords

[[CHOLEST 5 EN 3 OL 3 [(3 AMINOPROPYL)(4 ((3 AMINOPROPYL)AMINO)BUTYL]CARBAMATE]]; ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; BACTERIAL VECTOR; CYTOKERATIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENE THERAPY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LENTIVIRUS VECTOR; LIPID; LIPOSOME; LIPOXIN; LYSOPHOSPHATIDYLCHOLINE; MESSENGER RNA; PARVOVIRUS VECTOR; PLASMID VECTOR; POLYETHYLENEIMINE; RANTES; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN C; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AIRWAY; ALLOTRANSPLANTATION; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMNIOTIC FLUID CELL; ANTIGEN RECOGNITION; ARTICLE; ARTIFICIAL CHROMOSOME; BACTERIAL ARTIFICIAL CHROMOSOME; BACTERIAL INFECTION; BACTERIOPHAGE P1 ARTIFICIAL CHROMOSOME; BLOOD CLOTTING; BRAIN; BRONCHIOLE; BRONCHUS; CARCINOGENESIS; CELL NUCLEUS MEMBRANE; CELL THERAPY; CHROMATIN; CLONING VECTOR; CORD BLOOD STEM CELL TRANSPLANTATION; CYSTIC FIBROSIS; DNA VECTOR; DNA VIRUS; DUCHENNE MUSCULAR DYSTROPHY; EBOLA VIRUS; ECHOGRAPHY; ELECTROPHYSIOLOGY; EMBRYONIC STEM CELL; EPITHELIUM CELL; EPSTEIN BARR VIRUS; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL PIG; EXPRESSION VECTOR; EYE; FELINE IMMUNODEFICIENCY VIRUS; FERRET; FETUS; FLU LIKE SYNDROME; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC DISORDER; GERM LINE; GERM LINE GENE THERAPY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HEMOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; INTESTINE CELL; INTRON; KIDNEY; LENTIVIRINAE; LIVER; LUNG; LUNG DEVELOPMENT; LUNG DISEASE; MESENCHYMAL STEM CELL; METHYLATION; MITOSIS; MOUSE STRAIN; MUSCLE; MYCOSIS; NEUTROPHIL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NOSE MUCOSA; OVARY; PANCREAS; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 3; PHAGOSOME; PNEUMONIA; POSTNATAL DEVELOPMENT; PRENATAL CARE; PRENATAL DEVELOPMENT; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; REGENERATION; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROVIRUS; RNA VECTOR; RNA VIRUS; RODENT; SAFETY; SHEEP; STEM CELL; STEM CELL TRANSPLANTATION; TESTIS; THROMBOCYTE; TISSUE INJURY; TRANSCRIPTION INITIATION SITE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS REPLICATION; YEAST ARTIFICIAL CHROMOSOME;

ANIMALS; CHROMOSOMES, ARTIFICIAL, HUMAN; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HUMANS; STEM CELL TRANSPLANTATION;

EID: 79958107503     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60017-9     Document Type: Article

References (180)

1. Sheppard DN, Welsh MJ Structure and function of the CFTR chloride channel. Physiol Rev 1999, 79:S23-S45.
2. + conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest 1998, 102:15-21.
3. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channel. Science 1995, 269:847-850.
4. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell 1998, 95:1005-1015.
5. Quinton PM Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008, 372:415-417.
6. Wine JJ, Joo NS Submucosal glands and airway defense. Proc Am Thorac Soc 2004, 1:47-53.
7. Bragonzi A, Conese M Non-viral approach toward gene therapy of cystic fibrosis lung disease. Curr Gene Ther 2002, 2:295-305.
8. Griesenbach U, Ferrari S, Geddes DM, Alton EWFW Gene therapy progress and prospects: Cystic fibrosis. Gene Ther 2002, 9:1344-1350.
9. Griesenbach U, Geddes DM, Alton EW Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med 2004, 10:542-546.
10. Griesenbach U, Geddes DM, Alton EW Gene therapy for cystic fibrosis: an example for lung gene therapy. Gene Ther 2004, 11(Suppl l):S43-S50.
11. Griesenbach U, Alton EWFW Cystic fibrosis gene therapy: successes, failures and hopes for the future. Exp Rev Resp Med 2009, 3:363-371.
12. Knowles MR, Boucher RC Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002, 109:571-577.
13. Boucher RC An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002, 54:1359-1371.
14. Flotte TR, Ng P, Dylla DE, et al. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 2007, 15:229-241.
15. Flotte TR Adeno-associated virus-based gene therapy for inherited disorders. Pediatr Res 2005, 58:1143-1147.
16. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003, 14:1079-1088.
17. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multi-center, double-blind, placebo-controlled trial. Chest 2004, 125:509-521.
18. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007, 18:726-732.
19. Halbert CL, Allen JM, Miller AD Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001, 75:6615-6624.
20. Limberis MP, Wilson JM Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci U S A 2006, 103:12993-12998.
21. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 2009, 17:294-301.
22. Fischer AC, Smith CI, Cebotaru L, et al. Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther 2007, 15:756-763.
23. Song Y, Lou HH, Boyer JL, et al. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing. Hum Gene Ther 2009, 20:267-281.
24. Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005, 79:1113-1124.
25. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002, 76:5654-5666.
26. Kwilas AR, Yednak MA, Zhang L, et al. Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro. J Virol 2010, 84:7770-7781.
27. Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLos Biol 2009, 7:el000155.
28. Ferrari S, Griesenbach U, Iida A, et al. Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther 2007, 14:1371-1379.
29. Ferrari S, Griesenbach U, Shiraki-Iida T, et al. A defective nontrans-missible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther 2004, 11:1659-1664.
30. Griesenbach U, Boyton RJ, Somerton L, et al. Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration. Gene Ther 2006, 13:449-456.
31. Wilson JM Adeno-associated virus and lentivirus pseudotyped for lung-directed gene therapy. Proc Am Thorac Soc 2004, 1:309-314.
32. Copreni E, Penzo M, Carrabino S, Conese M Lentiviral-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of Cystic Fibrosis. Gene Ther 2004, 11:S67-S75.
33. Stocker AG, Kremer KL, Koldej R, Miller DS, Anson DS, Parsons DW Single-dose lentiviral gene transfer for lifetime airway gene expression. J Gene Med 2009, 11:861-867.
34. Limberis M, Anson DS, Fuller M, Parsons DW Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002, 13:1961-1970.
35. Rawlins EL, Hogan BL Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol 2008, 295:L231-L234.
36. Sinn PL, Arias AC, Brogden KA, McCray PB Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol 2008, 82:10684-10692.
37. Copreni E, Nicolis E, Tamanini A, et al. Late generation lentiviral vectors: evaluation of inflammatory potential in human airway epithelial cells. Virus Res 2009, 144:8-17.
38. Sinn PL, Shah AJ, Donovan MD, McCray PB Viscoelastic gel formulations enhance airway epithelial gene transfer with viral vectors. Am J Respir Cell Mol Biol 2005, 32:404-410.
39. Aarbiou J, van der Wegen P, Jorna H, Buijs-Offerman RM, Spijkers P Scholte BJ. In vivo lentiviral transduction of murine airway epithelial cells and lung monocytes is enhanced following naphthalene injury. Hum Gene Ther 2007, 18:983.
40. Kobinger GP, Weiner DJ, Yu QC, Wilson JM Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001, 19:225-230.
41. Medina MF, Kobinger GP, Rux J, et al. Lentiviral vectors pseudotyped with minimal filoviras envelopes increased gene transfer in murine lung. Mol Ther 2003, 8:777-789.
42. Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol 2005, 79:12818-12827.
43. Sinn PL, Penisten AK, Burnight ER, et al. Gene transfer to respiratory epithelia with lentivirus pseudotyped with Jaagsiekte sheep retrovirus envelope glycoprotein. Hum Gene Ther 2005, 16:479-488.
44. McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther 2006, 13:715-724.
45. Tarantal AF, McDonald RJ, Jimenez DF, et al. Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (Macaca mulatta): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery. Mol Ther 2005, 12:87-98.
46. Buckley SM, Howe SJ, Sheard V, et al. Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Ther 2008, 15:1167-1175.
47. Skarsgard ED, Huang L, Reebye SC, Yeung AY Jia WW Lentiviral vector-mediated, in vivo gene transfer to the tracheobronchial tree in fetal rabbits. J Pediatr Surg 2005, 40:1817-1821.
48. Mueller C, Strayer MS, Sirninger J, et al. In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors. Gene Ther 2010, 17:227-237.
49. Lee ER, Marshall J, Siegel CS, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996, 7:1701-1717.
50. Zabner J, Cheng SH, Meeker D, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1997, 100:1529-1537.
51. Alton EWFW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. The Lancet 1999, 353:947-954.
52. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008, 26:549-551.
53. Gill DR, Smyth SE, Goddard CA, et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin elongation factor la promoter. Gene Ther 2001, 8:1539-1546.
54. Alton EWFW Use of nonviral vectors for cystic fibrosis gene therapy. Proc Am Thorac Soc 2004, 1:296-301.
55. MacGregor G, Gray RD, Hilliard TN, et al. Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid. J Cyst Fibros 2008, 7:352-358.
56. Alton EW, Davies JC, Geddes DM Biomarkers for cystic fibrosis: are we progressing?. Am J Respir Crit Care Med 2007, 175:750-751.
57. Yamamoto A, Kormann M, Rosenecker J, Rudolph C Current prospects for mRNA gene delivery. Eur J Pharm Biopharm 2009, 71:484-489.
58. Mockey M, Goncalves C, Dupuy FP, Lemoine FM, Pichón C, Midoux P mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 2006, 340:1062-1068.
59. Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006, 108:4009-4017.
60. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007, 13:1745-1755.
61. Kuhn AN, Diken M, Kreiter S, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010, 17:961-971.
62. Van Tendeloo VF, Ponsaerts P, Berneman ZN mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 2007, 9:423-431.
63. Conese M, Boyd AC, Di Gioia S, Auriche C, Ascenzioni F Genomic context vectors and artificial chromosomes for cystic fibrosis gene therapy. Curr Gene Ther 2007, 7:175-187.
64. Sadoni N, Targosz BS, Englmann A, et al. Transcription-dependent spatial arrangements of CFTR and conserved adjacent loci are not conserved in human and murine nuclei. Chromosoma 2008, 117:381-397.
65. Zink D, Amaral MD, Englmann A, et al. Transcription-dependent spatial arrangements of CFTR and adjacent genes in human cell nuclei. J Cell Biol 2004, 166:815-825.
66. Anand R, Ogilvie DJ, Butler R, et al. A yeast artificial chromosome contig encompassing the cystic fibrosis locus. Genomics 1991, 9:124-130.
67. Manson AL, Trezise AE, MacVinish LJ, et al. Complementation of null CF mice with a human CFTR YAC transgene. EMBO J 1997, 16:4238-4249.
68. Chou JL, Rozmahel R, Tsui LC Characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene. J Biol Chem 1991, 266:24471-24476.
69. Vuillaumier S, Dixmeras I, Messai H, et al. Cross-species characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene reveals multiple levels of regulation. Biochem J 1997, 327:651-662.
70. Yoshimura K, Nakamura H, Trapnell BC, et al. The cystic fibrosis gene has a "housekeeping" -type promoter and is expressed at low levels in cells of epithelial origin. J Biol Chem 1991, 266:9140-9144.
71. Ott CJ, Blackledge NP, Leir SH, Harris A Novel regulatory mechanisms for the CFTR gene. Biochem Soc Trans 2009, 37:843-848.
72. Smith AN, Barth ML, McDowell TL, et al. A regulatory element in intron 1 of the cystic fibrosis transmemembrane conductance regulator gene. J Biol Chem 1996, 271:9947-9954.
73. Mogayzel PJ, Ashlock MA CFTR intron 1 increases luciferase expression driven by CFTR 5'-flanking DNA in a yeast artificial chromosome. Genomics 2000, 64:211-215.
74. Rowntree RK, Vassaux G, McDowell TL, et al. An element in intron 1 of the CFTR gene augments intestinal expression in vivo. Hum Mol Genet 2001, 10:1455-1464.
75. Blackledge NP, Ott CJ, Gillen AE, Harris A An insulator element 3' to the CFTR gene binds CTCF and reveals an active chromatin hub in primary cells. Nucleic Acids Res 2009, 37:1086-1094.
76. Lewandowska MA, Costa FF, Bischof JM, Williams SH, Soares MB, Harris A Multiple mechanisms influence regulation of the CFTR gene promoter. Am J Respir Cell Mol Biol 2010, 43:334-341.
77. Kazuki Y, Hiratsuka M, Takiguchi M, et al. Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol Ther 2010, 18:386-393.
78. Sachdeva R, Jonsson ME, Nelander J, et al. Tracking differentiating neural progenitors in pluripotent cultures using microRNA-regulated lentiviral vectors. Proc Natl Acad Sci U S A 2010, 107:11602-11607.
79. Harrington JJ, Van Bokkelen G, Mays RW, Gustashaw K, Willard HE Formation of de novo centromeres and construction of first-generation human artificial microchromosomes. Nat Genet 1997, 15:345-355.
80. Ikeno M, Grimes B, Okazaki T, et al. Construction of YAC-based mammalian artificial chromosomes. Nat Biotechnol 1998, 16:431-439.
81. Ebersole TA, Ross A, Clark E, et al. Mammalian artificial chromosome formation from circular alphoid input DNA does not require telomere repeats. Hum Mol Genet 2000, 9:1623-1631.
82. Nakano M, Cardinale S, Noskov VN, et al. Inactivation of a human kinetochore by specific targeting of chromatin modifiers. Dev Cell 2008, 14:507-522.
83. Grimes BR, Rhoades AA, Willard HE α-Satellite DNA and vector composition influence rates of human artificial chromosome formation. Mol Ther 2002, 5:798-805.
84. Okamoto Y, Nakano M, Ohzeki J, Larionov V, Masumoto H A minimal CENP-A core is required for nucleation and maintenance of a functional human centromere. EMBO J 2007, 26:1279-1291.
85. Grimes BR, Schindelhauer D, McGill NI, Ross A, Ebersole TA, Cooke HJ Stable gene expression from a mammalian artificial chromosome. EMBO Rep 2001, 2:910-914.
86. Mejia JE, Willmott A, Levy E, Earnshaw WC, Larin Z Functional complementation of a genetic deficiency with human artificial chromosomes. Am J Hum Genet 2001, 69:315-326.
87. Auriche C, Carpani D, Conese M, et al. Functional human CFTR produced by a stable minichromosome. EMBO Rep 2002, 3:862-868.
88. Ramalho A, Beck S, Schindelhauer D, Amaral MD. Sequence of CFTR Exons present in clones from PAC library RPCIP704. The European Working Group on CFTR Expression Virtual Repository F41, 2004 (). http://cfentraligcgulbenkianpt/cftr/vr/model.html.
89. Kotzamanis G, Abdulrazzak H, Gifford-Garner J, et al. CFTR expression from a BAC carrying the complete human gene and associated regulatory elements. J Cell Mol Med 2009, 13:2938-2948.
90. Auriche C, Di Domenico EG, Pierandrei S, et al. CFTR expression and activity from the human CFTR locus in BAC vectors, with regulatory regions, isolated by a single-step procedure. Gene Ther 2010, 17:1341-1354.
91. Laner A, Goussard S, Ramalho AS, et al. Bacterial transfer of large functional genomic DNA into human cells. Gene Ther 2005, 12:1559-1572.
92. Reyes-Sandoval A, Ertl HC CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol Ther 2004, 9:249-261.
93. Klinman DM, Klaschik S, Sato T, Tross D CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61:248-255.
94. Wilke M, Buijs-Offerman RM, Aarbiou J, et al. Mouse models of cystic fibrosis: Phenotypic analysis and research applications. J Cyst Fibros 2011, 10(Suppl 2):152-171.
95. Rochelle LG, Li DC, Ye H, Lee E, Talbot CR, Boucher RC Distribution of ion transport mRNAs throughout murine nose and lung. Am J Physiol Lung Cell Mol Physiol 2000, 279:L 14-L 24.
96. Borthwick DW, West JD, Keighren MA, Flockhart JH, Innes BA, Dorin JR Murine submucosal glands are clonally derived and show a cystic fibrosis gene-dependent distribution pattern. Am J Respir Cell Mol Biol 1999, 20:1181-1189.
97. Innes BA, Dorin JR Submucosal gland distribution in the mouse has a genetic determination localized on chromosome 9. Mamm Genome 2001, 12:124-128.
98. Boyd AC, Porteous DJ Revisiting the mouse lung model for CF. Gene Ther 2004, 11:737-738.
99. Klink D, Schindelhauer D, Laner A, et al. Gene delivery systems -gene therapy vectors for cystic fibrosis. J Cyst Fibros 2004, 3(Suppl 2):203-212.
100. Tate S, Elborn S Progress towards gene therapy for cystic fibrosis. Expert Opin Drug Deliv 2005, 2:269-280.
101. Griesenbach U, Sumner-Jones SG, Holder E, et al. Limitations of the murine nose in the development of nonviral airway gene transfer. Am J Respir Cell Mol Biol 2010, 43:46-54.
102. Di Gioia S, Conese M Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. Drug Des Develop Ther 2008, 2:163-188.
103. Carrabino S, Di Gioia S, Copreni E, Conese M Serum albumin enhances polyethylenimine-mediated gene delivery to human respiratory epithelial cells. J Gene Med 2005, 7:1555-1564.
104. Tagalakis AD, McAnulty RJ, Devaney J, et al. A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer. Mol Ther 2008, 16:907-915.
105. Price AR, Limberis MP, Wilson JM, Diamond SL Pulmonary delivery of adenovirus vector formulated with dexamethasone-spermine facilitates homologous vector re-administration. Gene Ther 2007, 14:1594-1604.
106. Kushwah R, Oliver JR, Cao H, Hu J Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways. Gene Ther 2007, 14:1243-1248.
107. Mueller C, Torrez D, Braag S, et al. Partial correction of the CFTR-dependent ABPA mouse model with recombinant adeno-associated virus gene transfer of truncated CFTR gene. J Gene Med 2008, 10:51-60.
108. Oreffo VI, Morgan A, Richards RJ Isolation of Clara cells from the mouse lung. Environ Health Perspect 1990, 85:51-64.
109. Mercer RR, Russell ML, Roggli VL, Crapo JD Cell number and distribution in human and rat airways. Am J Respir Cell Mol Biol 1994, 10:613-624.
110. McLachlan G, Baker A, Tennant P, et al. Optimizing aerosol gene delivery and expression in the ovine lung. Mol Ther 2007, 15:348-354.
111. Davidson H, Wilson A, Gray RD, et al. An immunocytochemical assay to detect human CFTR expression following gene transfer. Mol Cell Probes 2009, 23:272-280.
112. Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008, 321:1837-1841.
113. Stoltz DA Early pulmonary findings in a CFTR-/- pig. Pediatr Pulmonol Suppl 2009, 32:191.
114. Meyerholz DK, Ostedgaard LS, Chen J, et al. Early characterization of neonatal CFTR-/?F508 pigs. Pediatr Pulmonol Suppl 2009, 32:284.
115. Ostedgaard LS, Rogers CS, Dong Q, et al. Processing and function of CFTR-ΔF508 are species-dependent. Proc NatL Acad Sci U S A 2007, 104:15370-15375.
116. Liu Y, Wang Y, Jiang Y, et al. Mild processing defect of porcine ΔF508-CFTR suggests that ΔF508 pigs may not develop cystic fibrosis disease. Biochem Biophys Res Commun 2008, 373:113-118.
117. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transi Med 2010, 2:29ra31.
118. Sun X, Yan Z, Yi Y, et al. Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets. J Clin Invest 2008, 118:1578-1583.
119. Tripp RA, Tompkins SM Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009, 333:397-412.
120. Liu X, Sun X, Luo M, et al. Progress toward generating a CFTR null ferret model of cystic fibrosis with intestinal-specific expression of ferret CFTR. Pediatr Pulmonol Suppl 2009, 32:283.
121. Jaffe A, Prasad SA, Larcher V, Hart S Gene therapy for children with cystic fibrosis - who has the right to choose?. J Med Ethics 2006, 32:361-364.
122. Waddington SN, Kramer MG, Hernandez-Alcoceba R, et al. In utero gene therapy: current challenges and perspectives. Mol Ther 2005, 11:661-676.
123. Waddington SN, Nivsarkar MS, Mistry AR, et al. Permanent phenotypic correction of hemophilia B in immuno competent mice by prenatal gene therapy. Blood 2004, 104:2714-2721.
124. Tran ND, Porada CD, Almeida-Porada G, Glimp HA, Anderson WF, Zanjani ED Induction of stable prenatal tolerance to β-galactosidase by in utero gene transfer into preimmune sheep fetuses. Blood 2001, 97:3417-3423.
125. Waddington SN, Mitrophanous KA, Ellard FM, et al. Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. Gene Ther 2003, 10:1234-1240.
126. Tarantal AF, Lee CC, Jimenez DF, Cherry SR Fetal gene transfer using lentiviral vectors: in vivo detection of gene expression by microPET and optical imaging in fetal and infant monkeys. Hum Gene Ther 2006, 17:1254-1261.
127. Waddington S, Kramer MG, Hernandez-Alcoceba R, et al. In utero gene therapy: current challenges and perspectives. Mol Ther 2005, 11:661-676.
128. Buckley SM, Waddington SN, Jezzard S, et al. Factors influencing adenovirus-mediated airway transduction in fetal mice. Mol Ther 2005, 12:484-492.
129. Peebles D, Gregory LG, David A, et al. Widespread and efficient marker gene expression in the airway epithelia of fetal sheep marker gene expression in the airway epithelia of fetal sheep after minimally invasive trachéal application of recombinant adenovirus in utero. Gene Ther 2004, 11:70-78.
130. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
131. Themis M, Waddington SN, Schmidt M, et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 2005, 12:763-771.
132. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317:477.
133. Porada CD, Park PJ, Tellez J, et al. Male germ-line cells are at risk following direct-injection retroviral-mediated gene transfer in utero. Mol Ther 2005, 12:754-762.
134. Lee CC, Jimenez DF, Kohn DB, Tarantal AF Fetal gene transfer using lentiviral vectors and the potential for germ cell transduction in rhesus monkeys (Macaca mulatta). Hum Gene Ther 2005, 16:417-425.
135. r gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Hum Gene Ther 1998, 9:1571-1585.
136. Gonzaga S, Henriques-Coelho T, Davey M, et al. Cystic adenomatoid malformations are induced by localized FGF10 overexpression in fetal rat lung. Am J Respir Cell Mol Biol 2008, 39:346-355.
137. Porada CD, Park PJ, Almeida-Porada G, et al. Gestational age of recipient determines pattern and level of transgene expression following in utero retroviral gene transfer. Mol Ther 2005, 11:284-293.
138. Broackes-Carter FC, Mouchel N, Gill D, Hyde S, Bassett J, Harris A Temporal regulation of CFTR expression during ovine lung development: implications for CF gene therapy. Hum Mol Genet 2002, 11:125-131.
139. Painter RG, Valentine VG, Lanson NA, et al. CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 2006, 45:10260-10269.
140. Conese M, Copreni E, Di Gioia S, De Rinaldis P, Fumarulo R Neutrophil recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung disease. J Cyst Fibros 2003, 2:129-135.
141. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006, 8:933-944.
142. von Hundelshausen P, Weber C Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007, 100:27-40.
143. Mattoscio D, Evangelista V, De Cristofaro R, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J 2010, 24:3970-3980.
144. Nichols DP, Konstan MW, Chmiel JF Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin Rev Allergy Immunol 2008, 35:135-153.
145. Conese M, Romano M, Furnari ML, et al. New genetic and pharmacological treatments for cystic fibrosis. Curr Ped Rev 2009, 5:8-27.
146. Flinn IW, Berdeja JG Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma. Cancer Treat Res 2006, 131:251-281.
147. Kokhaei P, Palma M, Mellstedt H, Choudhury A Biology and treatment of chronic lymphocytic leukemia. Ann Oncol 2005, 16(Suppl 2):ii 113-ii 123.
148. Nelson DL, Notarangelo LD Overview of immunodeficiency diseases where bone marrow transplantation is feasible. Bone Marrow Transplant 1989, 4(Suppl 4):132.
149. Issaragrisil S Stem cell transplantation for thalassemia. Int J Hematol 2002, 76(Suppl l):307-309.
150. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005, 352:2069-2081.
151. Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004, 350:1960-1969.
152. Biffi A, Cesani M Human hematopoietic stem cells in gene therapy: pre-clinical and clinical issues. Curr Gene Ther 2008, 8:135-146.
153. van Til NP, Stok M, Aerts Kaya FS, et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood 2010, 115:5329-5337.
154. Conese M, Copreni E, Piro D, Rejman J Gene and cell therapy for the treatment of cystic fibrosis. Adv Gene Mol Cell Ther 2007, 1:99-119.
155. Piro D, Rejman J, Conese M Stem cell therapy for cystic fibrosis: current status and future prospects. Exp Rev Resp Med 2008, 2:365-380.
156. Rejman J, Colombo C, Conese M Engraftment of bone marrow-derived stem cells to the lung in a model of acute respiratory infection by Pseudomonas aeruginosa. Mol Ther 2009, 17:1257-1265.
157. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007, 179:1855-1863.
158. Leblond AL, Naud P, Forest V, et al. Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury. Hum Gene Ther 2009, 20:1329-1343.
159. Wong AP, Dutly AE, Sacher A, et al. Targeted cell replacement with bone marrow cells for airway epithelial regeneration. Am J Physiol Lung Cell Mol Physiol 2007, 293:L740-L752.
160. Sueblinvong V, Loi R, Eisenhauer PL, et al. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 2008, 177:701-711.
161. Carraro G, Perin L, Sedrakyan S, et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells 2008, 26:2902-2911.
162. Grove JE, Lutzko C, Priller J, et al. Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary epithelium. Am J Respir Cell Mol Biol 2002, 27:645-651.
163. Cavazzana-Calvo M, Fischer A Gene therapy for severe combined immunodeficiency: are we there yet?. J Clin Invest 2007, 117:1456-1465.
164. Loi R, Beckett T, Goncz KK, Suratt BT, Weiss DJ Limited restoration of cystic fibrosis lung epithelium in vivo with adult marrow derived cells. Am J Respir Crit Care Med 2006, 173:171-179.
165. Bruscia EM, Price JE, Cheng E-C, et al. Assessment of cystic fibrosis transmembrane conductance regulator (CFTR) activity in CFTR-null mice after bone marrow transplantation. Proc Natl Acad Sci USA 2006, 103:2965-2970.
166. Bruscia EM, Ziegler EC, Price JE, Weiner S, Egan ME, Krause DS Engraftment of donor-derived epithelial cells in multiple organs following bone marrow transplantation into newborn mice. Stem Cells 2006, 24:2299-2308.
167. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992, 2:21-25.
168. - transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005, 289:L1123-L1130.
169. Johnson LG, Boyles SE, Wilson J, Boucher RC Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995, 95:1377-1382.
170. Goldman MJ, Yang Y, Wilson JM Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. Nat Genet 1995, 9:126-131.
171. Weiss DJ, Berberich MA, Borok Z, et al. Adult stem cells, lung biology, and lung disease. NHLBI/Cystic Fibrosis Foundation Workshop. Proc Am Thorac Soc 2006, 3:193-207.
172. -/- mice. Am J Respir Cell Mol Biol 2009, 40:295-304.
173. Wang G, Bunnell BA, Painter RG, et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci U S A 2005, 102:186-191.
174. Hung SC, Pochampally RR, Chen SC, Hsu SC, Prockop DJ Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25:2363-2370.
175. Inoue Y, Iriyama A, Ueno S, et al. Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration. Exp Eye Res 2007, 85:234-241.
176. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-F42.
177. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003, 100:8407-8411.
178. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007, 4:e269.
179. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007, 104:11002-11007.
180. Uccelli A, Pistoia V, Moretta L Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol 2007, 28:219-226.